Lv7
4540 积分 2023-07-31 加入
Efficacy of Risankizumab Dose Escalation Among Patients With Inflammatory Bowel Disease
2个月前
已完结
Predicting Human Bioavailability of Subcutaneously Administered Monoclonal Antibodies Using Non-human Primate Linear Clearance and Antibody Isoelectric Point
3个月前
已完结
Safety and pharmacokinetics of IBI112, an IL-23 monoclonal antibody, in Chinese healthy volunteers: a first-in-human phase 1 study
3个月前
已完结
63386 Phase I single and multiple ascending-dose study to assess the safety, tolerability and pharmacokinetics of LAD191, a monoclonal antibody against the interleukin-1 receptor accessory protein (IL-1RAP), in healthy volunteers
4个月前
已关闭
皖公网安备34019202002308
